In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumour progression following recurrence of the liver disease. The findings were published in the Journal of Viral Hepatitis.
Led by Norifumi Kawada, professor of the Department of Hepatology, the study investigated the effect eliminating HCV had on tumour progression* of early-stage HCC. “DAA therapy is effective at eradicating the hepatitis C virus, a major risk factor for HCC” says Professor Kawada. “While it is deemed low or inconclusive whether DAA therapy helps prevent HCC recurrence, little is known about how the antiviral therapy affects progression of the liver disease after cancer treatment.”
165 patients with early-stage HCC, who were also receiving curative HCC treatment, enrolled in the study. After treatment, 72 patients received DAA therapy while the remaining 93 did not. The team recorded 96 HCC recurrences with approximately 75% of them at an early stage according to the Barcelona Clinic Liver Cancer staging system.
To account for bias inherent in a single-centre retrospective study, a multivariate adjusted time-varying Cox regression analysis showed a 72% reduction in tumour progression in the DAA-treated group and an 88% reduction in risk of death from HCC. Also, the frequency of cancer treatments given before the cancer progressed saw a 59% decrease, from 0.83 treatments per year in patients who did not receive DAA therapy to 0.24 treatments per year in patients who did.
“Usually, cancer cells grow over long periods of time before they can be detected as a tumour,” states first author Hiroko Ikenaga. “Our study showed that eliminating the hepatitis C virus with DAA suppresses tumour progression, which we suggest contributes to overall patient survival.”
HCV infection affects 71 million people worldwide and accounts for about 65% of the causes of liver cancer in Japan. While the team will continue to investigate issues like the extent to which liver cirrhosis and function improve after the antiviral treatment, as supporting author and Lecturer Sawako Uchida-Kobayashi puts it, “the suppressing effect of DAA therapy on cancer progression revealed by our study gives us hope to improve the overall quality of life for people with HCC.”
*Tumour progression was defined as when HCC progresses to more than 4 nodules in the liver, portal invasion or extrahepatic metastasis.
Source: Osaka City University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.